Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”) ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 ...
Hello, and welcome to Travere Therapeutics First Quarter 2026 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference call over to Nivi ...
Palisades added 137,768 shares of Travere Therapeutics; estimated trade size $5.26 million based on quarterly average price. The position represents 1.99% of 13F assets under management (AUM). Travere ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results